Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given an average recommendation of “Hold” by the fourteen research firms that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $26.13.

VYGR has been the subject of a number of research analyst reports. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Stifel Nicolaus initiated coverage on Voyager Therapeutics in a research note on Friday, July 28th. They issued a “buy” rating and a $20.00 target price for the company. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research note on Friday, October 27th. They issued a “buy” rating and a $35.00 target price for the company. ValuEngine upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Finally, Chardan Capital restated a “hold” rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th.

TRADEMARK VIOLATION WARNING: This news story was published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/analysts-set-voyager-therapeutics-inc-vygr-price-target-at-26-13/1722471.html.

Voyager Therapeutics (NASDAQ VYGR) traded up $0.28 during trading on Monday, hitting $14.18. The stock had a trading volume of 330,000 shares, compared to its average volume of 241,914. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99.

In related news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total value of $54,900.00. Following the completion of the transaction, the insider now owns 17,157 shares in the company, valued at approximately $171,570. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 38,430 shares of company stock valued at $562,890 in the last 90 days. 8.00% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of VYGR. Bank of New York Mellon Corp raised its stake in Voyager Therapeutics by 15.6% in the 1st quarter. Bank of New York Mellon Corp now owns 44,018 shares of the company’s stock worth $582,000 after acquiring an additional 5,952 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Voyager Therapeutics by 3.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 28,921 shares of the company’s stock valued at $383,000 after buying an additional 1,026 shares during the last quarter. Hershey Trust Co. raised its stake in shares of Voyager Therapeutics by 163.0% during the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Voyager Therapeutics by 57.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Voyager Therapeutics by 148.1% during the 2nd quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock valued at $402,000 after buying an additional 26,763 shares during the last quarter. Institutional investors own 37.04% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.